Not a good buy right now: price is breaking down into/through near-term support while bearish momentum is still expanding.
If you must act immediately (impatient entry), GLUE is better treated as a watch/hold until it reclaims ~19.62 (S1) and stabilizes; otherwise downside risk skews toward ~18.14 (S2).
Options positioning is modestly constructive (OI put/call 0.6) and IV is relatively cheap, but that alone isn’t enough to override the current technical damage and lack of near-term catalysts.
Technical Analysis
Trend/momentum: Strong bearish near-term move (regular session -6.64%); MACD histogram -0.635 and negatively expanding = downside momentum still building.
RSI: RSI(6) ~25.56 (oversold territory), which can spark bounces, but oversold can persist in breakdowns.
Moving averages: Converging MAs suggests indecision/transition, not a confirmed uptrend.
Levels: Price ~19.53 is slightly below S1 19.619 (failed/fragile support). Next support S2 ~18.144. Key pivot overhead ~22.007; resistance levels 24.394 and 25.869.
Pattern-based bias (provided): ~-3% next week expectation and only modest +3.3% next month odds suggests choppy/weak near-term follow-through.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: OI put/call 0.6 is call-leaning (mildly bullish positioning). Volume put/call 0.89 is closer to neutral/slightly put-leaning on the day.
Activity: Today’s options volume 17 vs 30-day average factor 2.19 (uptick in attention, but still small absolute volume).
Volatility: IV30 ~89.29 vs HV ~128.66; IV percentile ~17.93 / IV rank ~10.82 indicates IV is relatively low vs its own history (options not “expensive”).
Takeaway: Options are not flashing panic; positioning slightly constructive, but not a strong bullish timing signal by itself.
Technical Summary
Sell
5
Buy
8
Positive Catalysts
Pipeline catalyst path highlighted by Wells Fargo: MRT-8102 Phase 1 update expected in 1H 2026 (potential de-risking event).
Potential disclosure of Novartis plans for MRT-6160 (partner-driven catalyst).
Oversold RSI increases probability of a short-term technical rebound if price reclaims S1 and holds.
Neutral/Negative Catalysts
can keep price swings sharp and trend-following to the downside.
Profitability: Net income -27.081M, +13.50% YoY (loss narrowing/improving).
EPS: -0.33, +13.79% YoY (improving, still loss-making).
Gross margin: 100% (consistent with collaboration/other revenue mix; not the key constraint—R&D spend remains the driver).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Latest notable action: (2025-12-16) Wells Fargo upgraded to Overweight from Equal Weight; price target $22.
Ratings/targets trend: recent data shows a positive directional change (upgrade) with a target above current price (~19.53), implying upside if 2026 catalysts de-risk.
Wall Street pros: identifiable 2026 catalyst calendar (MRT-8102 update), potential partner clarity (Novartis/MRT-6160), improving YoY loss metrics.
Wall Street cons: near-term execution/timing risk (catalysts are not immediate), and the stock is currently trading with weak technicals that can overpower fundamentals in the short run.
Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is 30.4 USD with a low forecast of 20 USD and a high forecast of 37 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast GLUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLUE is 30.4 USD with a low forecast of 20 USD and a high forecast of 37 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.900
Low
20
Averages
30.4
High
37
Current: 18.900
Low
20
Averages
30.4
High
37
Wells Fargo
Equal Weight -> Overweight
upgrade
$22
AI Analysis
2025-12-16
Reason
Wells Fargo
Price Target
$22
AI Analysis
2025-12-16
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo upgraded Monte Rosa Therapeutics (GLUE) to Overweight from Equal Weight with a $22 price target. The firm cites the company's catalyst path in 2026 for the upgrade. Wells sees upside from MRT-8102's Phase 1 update in the first half of 2026 and likely disclosure of Novartis' (NVS) plans for MRT-6160. The MRT-8102 Phase 1 update should be "de-risking," the analyst tells investors in a research note.
Wedbush
Robert Driscoll
Buy
Maintains
$15 → $17
2025-03-21
Reason
Wedbush
Robert Driscoll
Price Target
$15 → $17
2025-03-21
Maintains
Buy
Reason
Wedbush raised the firm's price target on Monte Rosa Therapeutics to $17 from $15 and keeps an Outperform rating on the shares after the company reported Q4 financials and provided clinical updates for its VAV1 and MRT-2359 programs in immunology and oncology, respectively. Monte Rosa shared healthy volunteer data for its MRT-6160 VAV1 degrader program showing a favorable safety profile, along with deep VAV1 degradation of over 90% and substantial ablation of T and B cell function shown by reduction in cytokine release from T and B cells following ex vivo stimulation, the firm notes. Taken together, Wedbush sees these data as providing robust support for further evaluation of the molecule in Phase 2 studies in immune mediated diseases, including autoimmune indications such as colitis and rheumatoid arthritis.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GLUE
